Healthcare / Drug Manufacturers - GeneralNSE
$4586.70
-1.80 (-0.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$105.8B
P/E
41.0x
↑EV/EBITDA
30.6x
↑ROE
62.5%
↑Gross Margin
73.8%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+27.0%
FCF CAGR
—
FCF margin
19.0%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.78B · net income $2.40B · FCF $1.67B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $8.78B | $8.78B | $7.25B | $5.44B |
| Net Income | $2.40B | $2.40B | $1.81B | $1.65B |
| EBITDA | $3.34B | $3.34B | $2.55B | $2.21B |
| EPS | 104.27 | 104.27 | 78.59 | 71.60 |
| Gross Margin | 73.8% | 73.8% | 74.3% | 64.4% |
| Operating Margin | 33.8% | 33.8% | 36.7% | 39.9% |
| Net Margin | 27.3% | 27.3% | 25.0% | 30.3% |
| Balance Sheet | ||||
| Debt/Equity | 0.06 | 0.06 | 0.07 | — |
| Cash Flow | ||||
| Free Cash Flow | $1.67B | $1.67B | $4.29B | $-44.0M |
| Returns | ||||
| ROE | 62.5% | 62.5% | 66.3% | 79.4% |
| Valuation | ||||
| P/E | 40.97 | 40.97 | 62.47 | — |
| EV/EBITDA | 30.57 | 30.57 | 43.11 | — |
| P/B | 27.50 | 27.50 | 41.42 | — |
| Growth & Yield | ||||
| Revenue Growth | 21.2% | 21.2% | 33.1% | — |
| EPS Growth | 32.7% | 32.7% | 9.8% | — |
| Dividend Yield | 1.6% | 1.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
57.4%
EPS terminal req.
$406.99
Spread vs growth
-24.8%
5Y implied EPS CAGR
36.4%
EPS terminal req.
$492.46
Spread vs growth
-3.7%
10Y implied EPS CAGR
22.5%
EPS terminal req.
$793.11
Spread vs growth
10.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.5%
Start / end P/E
64.2x → 44.0x
EPS bridge
78.59 → 104.27
Residual
-10.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.